
Nuvation Bio NUVB
$ 4.52
1.8%
Annual report 2025
added 03-02-2026
Nuvation Bio Long Term Debt Current 2011-2026 | NUVB
Annual Long Term Debt Current Nuvation Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.88 M | 1.66 M | 1.97 M | 1.21 M | 863 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.97 M | 863 K | 1.52 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.16 | 1.46 % | $ 445 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
675 K | $ 9.77 | 1.82 % | $ 632 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 98.14 | -5.13 % | $ 27.2 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 22.15 | -1.36 % | $ 3.67 B | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Cerus Corporation
CERS
|
2.9 M | $ 2.79 | 37.44 % | $ 532 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | ||
|
Calithera Biosciences
CALA
|
1.37 M | - | -10.95 % | $ 876 K | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
CymaBay Therapeutics
CBAY
|
7 K | - | - | $ 3.45 B | ||
|
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | ||
|
Caladrius Biosciences
CLBS
|
137 K | - | -16.75 % | $ 25.8 M | ||
|
Cardiff Oncology
CRDF
|
730 K | $ 1.72 | -0.87 % | $ 115 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
3.5 M | - | - | $ 2.18 B | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Dynavax Technologies Corporation
DVAX
|
4.18 M | - | - | $ 2.02 B | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 2.93 | -8.15 % | $ 4.82 M | ||
|
Eiger BioPharmaceuticals
EIGR
|
84 K | - | -9.21 % | $ 2.55 M | ||
|
Editas Medicine
EDIT
|
6.03 M | $ 2.9 | -3.48 % | $ 257 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
712 K | - | -5.68 % | $ 8.28 M | ||
|
Edesa Biotech
EDSA
|
19.9 K | $ 17.81 | -2.57 % | $ 56.9 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M |